Injectable Drug Delivery Market Size, Share, and Trends 2024 to 2034

Injectable Drug Delivery Market Size and Growth 2023 to 2032

The global injectable drug delivery market size was valued at US$ 600 billion in 2022 and is expected to hit US$ 1388.13 billion by 2032 with a CAGR of 8.80% from 2023 to 2032.

Key Takeaways:

• North America has accounted 46% revenue share in 2022.
• By device type, the prefilled syringes segment has held market share of over 58% in 2022 and it is growing at a CAGR of 9.5% over the forecast period.
• By therapeutic application, the oncology segment has held highest revenue share 44% in 2022.
• By distribution channel, the hospitals and clinics segment has captured market share of around 61% in 2022.

Growth Factors

One of the significant factors driving the growth of global injectable drug delivery market is growing prevalence of cancer. According to the International Agency for Research on Cancer, 1 in 5 individuals will develop cancer throughout their lifetime by December 2020, with 1 in 8 men and 1 in 11 women dying from the disease worldwide. As per the International Agency for Research, global cancer cases and deaths will increase to 19.3 million cases and 10 million deaths in 2020, up from 18 million cases and deaths in 2018. In addition, the key market players are concentrating on new product development and launches. For example, the U.S. Food and Drug Administration authorized Apretude for pre-exposure prophylaxis to lower the risk of sexually acquired HIV in adults weighing at least 35 kg in December 2021.

The COVID-19 epidemic has had both beneficial and negative consequences on the healthcare sector. The expanding COVID-19 patient population is putting strain on healthcare systems. Due to increased demand for medical goods such as pre-filled syringes and injections, manufacturers have increased their production capacity to keep up with demand. Furthermore, the government all around the world is contributing towards the growth of global injectable drugs delivery market. The government is heavily investing for the development and launch of novel injectable drugs delivery in the market.

Due to the broad product portfolio and impressive distribution network of large businesses in both emerging and established nations, the competitive rivalry of the global injectable drugs delivery market is unified in nature. Some of the primary strategies followed by major market players include the significant funding for the development of innovative and latest technologies, as well as the introduction of unique goods such as sophisticated wearable medical devices and gadgets.

Infant Injectable Drug Delivery Market Scope

Type Insights

The devices segment accounted largest revenue share in 2022. The growing prevalence of chronic disorders is leadingto an increase in overall syringe practice, predominantly disposable syringes. The cardiovascular illnesses, diabetes, and obesity have been found to be leading causes of death from chronic disorders. As populacesurge is believed to be the critical factor in emerging nations, this is likely to have the highest impact all around the world.

The formulations segment is fastest growing segment of the injectable drugs delivery market in 2022. The growing prevalence of chronic disorders, increased acceptance of self-injection, patient adherence, biologics, and innovative technologies are all factors driving this segment’s rapid rise.

Therapeutic Application Insights

The auto-immune diseases segment accounted revenue share in 2022. The immune system attacks and destroys its own body tissue in autoimmune diseases. The diabetes, lupus, rheumatoid arthritis, and other auto-immune diseases are among the most frequent. Immune suppressants, anti-inflammatory medicines, and other medications have been licensed to treat auto-immune illness.

The oncology segment is fastest growing segment of the injectable drugs delivery market in 2020. The growing prevalence of cancer is driving the growth of the segment. As per the American Cancer Society, by 2020, there will be roughly 1,806,590 cancer patients in the U.S. alone, up 31% from 2010.

Distribution Channel Insights

The hospitals segment dominated the injectable drugs delivery market in 2022. This is attributed to an increase in the number of people admitted to hospitals with acute and chronic wounds. In addition, expansion of the segment is also being driven by the surge in the number of standalone clinics in established and developing nations.

The retail pharmacy stores segment is expected to strong growth over the forecast period. The retail pharmacy stores sell pharmaceutical medications and drugs. These stores offer generic and branded medications, as well as other pharmaceutical supplies. The growing preference of patients for buying injectable drugs delivery from these stores is driving the growth of the segment. In addition, growing consumption of over the counter drugs is also contributing towards the expansion of the retail pharmacy stores segment.

Region Insights

North America dominated the injectable drugs delivery market in 2022. The growth of injectable drugs delivery market in North America region is being attributed to the growing prevalence of various disorders. According to the Alzheimer’s Association, about 6.2 million Americans aged 65 and older will have Alzheimer’s disease by 2020. There are 3.8 million women and 2.4 million men among them. In addition, rising adoption of strategies by market players are also supporting the growth of North America injectable drugs delivery market. Piramal Critical Care teamed with Medivant Healthcare, a pharmaceutical outsourcing facility based in the U.S., in July 2020 to solve the significant shortage of injectable medications in hospitals across the country.

Europe, on the other hand, is expected to develop at the fastest rate during the forecast period. The UK dominates the injectable drugs delivery market in Europe region. The Europe injectable drugs delivery market is attributed to the factors such as the rise of the biologics market, rising incidence of chronic disorders, and the rising demand for self-injection devices are all contributing to this trend. The other factors propelling the growth of injectable drugs delivery market in Europe region are rising disposable income, rising number of partnerships, and rising awareness about safety and comfort.

Key Developments

• BD bought CareFusion Corporation in March 2015 to broaden its capabilities and improve drug management and patient safety. In the same year, BD purchased CRISI Medical Systems, a medical technology business, in order to improve the efficiency of drug delivery via IV injectables. BD has a worldwide presence in 50 nations, allowing it to maintain its position in the global market.
• Pfenex Inc. announced in June 2020 that Alvogen, its commercialization partner, had introduced Teriparatide Injection in the U.S. for a variety of indications, including postmenopausal women with osteoporosis who are at high risk of broken bones.
• Terumo Corporation teamed up with Ypsomed Group in 2014. The organization combined their prefillable polymer syringe, PLAJEX, with YpsoMate as a result of this agreement. This aided the corporation in strengthening their syringe product offerings.
• Sanford-Burnham Medical Research Institute and Eli Lilly and Company formed a partnership in 2015 to explore immunological therapeutics for inflammatory bowel disorder, lupus, and autoimmune diseases. The expertise of both institutions will be pooled to discover novel treatments for these disorders. 

Infant Injectable Drug Delivery Market Companies

• Becton
• Dickinson and Company
• Pfizer Inc.
• Teva Pharmaceuticals Industries Ltd.
• Eli Lilly and Company
• Baxter International, Inc.
• Sandoz
• Terumo
• Schott AG
• Gerresheimer
• Ypsomed
• Bespak
• B. Braun Melsungen

Segments Covered in the Report

By Type

• Devices
  • Conventional Injectables
  • Pre-Filled Syringes
  • Auto-Injectors
  • Pen-Injectors
• Formulations

By Formulation Packaging

• Ampules
• Vials
• Cartridges
• Bottles

By Therapeutic Application

• Auto-immune diseases
• Hormonal Disorders
• Orphan Diseases
• Oncology
• Others

By Usage Pattern

• Curative Care
• Immunization
• Other

By Site of Administration

• Skin
• Circulatory/Musculoskeletal
• Organs
• Central Nervous System

By Distribution Channel

• Hospitals & Clinics
• Retail Pharmacy Stores
• Others

By Facility of Use

• Hospitals & Clinics
• Home Care Settings
• Other

 By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa